{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-117568","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2024-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.054186+00:00","generated_at":"2026-05-30T09:37:06.108393+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"EyePoint reports positive Phase 2 VERONA interim data for DURAVYU in DME; +8.9 letters BCVA","bullets":["DURAVYU 2.7mg showed +8.9 letter improvement in BCVA vs +3.2 for aflibercept control at 16 weeks.","CST reduction of 68.1 microns vs 30.5 microns for control.","82% of DURAVYU 2.7mg eyes were supplement-free vs 50% for control at 16 weeks.","No DURAVYU-related ocular or systemic SAEs reported; no endophthalmitis, vasculitis, or IOI.","Full topline data from VERONA expected in Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-117568","json":"https://secwatch.observer/filing/0000950170-24-117568.json","markdown":"https://secwatch.observer/filing/0000950170-24-117568.md","text":"https://secwatch.observer/filing/0000950170-24-117568.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024117568/0000950170-24-117568-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024117568/eypt-20241028.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:37:06.108393+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}